Avalo Therapeutics Inc (AVTX) — Who's Buying and Selling (13F, Q2 2026)

AVTX ranks #4004 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

130 institutions disclose a position in AVTX, but none treat it as a major bet — even Velan Capital Investment Management LP, its most concentrated holder, allocates just 3.6% of its own portfolio to it.

Fidelity has added to its AVTX position for two straight quarters, increasing it by $90.3M to reach $94.3M today.

Morgan Stanley has trimmed its AVTX position for two straight quarters, cutting it by $2.4M while still holding $2.4M.

AVTX is up 2.1% today, and institutions have been net buyers of $804.9M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

AVTX reported a net loss of $100.3M over the trailing twelve months.

• Not yet profitable — net loss of $100.3M over the trailing twelve months
• Revenue grew 13.4% year over year
• Net income declined year over year, from -$46.2M to -$100.3M
• Operating cash flow was negative, using $51.5M in cash
• Current ratio of 8.14x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.40x equity — within a conventional range